您好,欢迎来到试剂仪器网! [登录] [免费注册]
试剂仪器网
位置:首页 > 产品库 > Benazepril-d5(hydrochloride)
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
Benazepril-d5(hydrochloride)
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
Benazepril-d5(hydrochloride)图片
CAS NO:1279026-26-4
包装:1mg
市场价:4158元

产品介绍
An internal standard for the quantification of benazapril
Cas No.1279026-26-4
别名贝那普利杂质,CGS14824A-d5 hydrochloride
Canonical SMILESO=C(OCC)[C@@H](N[C@H]1CCC2=C(C=CC=C2)N(CC(O)=O)C1=O)CCC3=C([2H])C([2H])=C([2H])C([2H])=C3[2H].Cl
分子式C24H23D5N2O5.HCl
分子量466
溶解度DMSO: slightly soluble,Ethanol: slightly soluble,Methanol: slightly soluble
储存条件Store at -20°C
General tipsFor obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.
Shipping ConditionEvaluation sample solution : ship with blue ice
All other available size: ship with RT , or blue ice upon request
产品描述

Benazepril-d5is intended for use as an internal standard for the quantification of benazepril . Benazepril is a prodrug of the angiotensin converting enzyme (ACE) inhibitor benazeprilat .1It is metabolized to benazeprilat by hepatic esterases. Benazepril inhibits thein vitroenzymatic activity of partially purified ACE isolated from rabbit lung (IC50= 2 nM).2It decreases the triglyceride and total cholesterol levels in normotensive rats when administered at a dose of 30 mg/kg and decreases aortic atherosclerosis in cholesterol-fed rabbits when administered at a dose of 3 mg/kg per day.3Benazepril (0.1-10 mg/kg per day) reduces blood pressure in spontaneously hypertensive rats.4It also decreases proteinuria in cats with chronic kidney disease when administered at doses ranging from 0.5 to 1 mg/kg per day.5Formulations containing benazepril have been used to treat hypertension, congestive heart failure, and chronic kidney disease in both human and veterinary medicine.

1.Toutain, P.L., and LefÈbvre, H.P.Pharmacokinetics and pharmacokinetic/pharmacodynamic relationships for angiotensin-converting enzyme inhibitorsJ. Vet. Pharmacol. Ther.27(6)515-525(2004) 2.Ksander, G.M., Erion, M., Yuan, A.M., et al.Dual angiotensin converting enzyme/thromboxane synthase inhibitorsJ. Med. Chem.37(12)1823-1832(1994) 3.Yamamoto, S., Takemori, E., Hasegawa, Y., et al.General pharmacology of the novel angiotensin converting enzyme inhibitor benazepril hydrochloride. Effects on cardiovascular, visceral and renal functions and on hemodynamicsArzneimittelforschung41(9)913-923(1991) 4.Watthey, J.W.H., Stanton, J.L., Desai, M., et al.Synthesis and biological properties of (carboxyalkyl)amino-substituted bicyclic lactam inhibitors of angiotensin converting enzymeJ. Med. Chem.28(10)1511-1516(1985) 5.King, J.N., Gunn-Moore, D.A., Tasker, S., et al.Tolerability and efficacy of benazepril in cats with chronic kidney diseaseJ. Vet. Intern. Med.20(5)1054-1064(2006)